Targeting IL-1 in Sjögren's syndrome

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 4, 2013, Pages 393-401

  Yamada, Akiko ^a   Arakaki, Rieko ^a   Kudo, Yasusei ^a   Ishimaru, Naozumi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Autoimmunity; IL 1; Sj gren's syndrome

Indexed keywords

CYTOKINE; GLUCOSE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 36; UNCLASSIFIED DRUG;

APOPTOSIS; BASAL METABOLIC RATE; BLOOD PRESSURE; BONE REMODELING; CARCINOGENESIS; CELL ACTIVATION; CELL DAMAGE; CELL DEATH; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; EPITHELIUM CELL; EXOCRINE CELL; FATIGUE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; IRON METABOLISM; KERATINIZATION; MEDICAL DECISION MAKING; NEUROENDOCRINE SYSTEM; NOCICEPTION; NONHUMAN; OCULAR SURFACE DISEASE; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SQUAMOUS CELL METAPLASIA; TARGET ORGAN; THERMOREGULATION;

ANIMALS; ANTIRHEUMATIC AGENTS; HUMANS; INTERLEUKIN-1; LACRIMAL APPARATUS; MOLECULAR TARGETED THERAPY; MUCOUS MEMBRANE; PROTEIN ISOFORMS; RECEPTORS, INTERLEUKIN-1; SALIVARY GLANDS; SIGNAL TRANSDUCTION; SJOGREN'S SYNDROME;

EID: 84875197221     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.754427     Document Type: Review

References (114)

1. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004;4:371-9
2. Luheshi GN. Cytokines and fever. Mechanisms and sites of action. Ann N Y Acad Sci 1998;856:83-9
3. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107
4. Plante GE. Depression and cardiovascular disease: A reciprocal relationship. Metabolism 2005;54:45-8
5. Deicher R, Horl WH. New insights into the regulation of iron homeostasis. Eur J Clin Invest 2006;36:301-9
6. Schett G. Effects of inflammatory and anti-inflammatory cytokines on the bone. Eur J Clin Invest 2011;41:1361-6
7. Besedovsky HO, Del Rey A. Interleukin-1 resets glucose homeostasis at central and peripheral levels: Relevance for immunoregulation. Neuroimmunomodulation 2010;17:139-41
8. Vendramini-Costa DB, Carvalho JE. Molecular Link Mechanisms between Inflammation and Cancer. Curr Pharm Des 2012;18:3831-52
9. Akdis M, Burgler S, Crameri R, et al. Interleukins, from 1 to 37, and interferon-gamma: Receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011;127:701-21.e701-70
10. Cooper AM. T cells in mycobacterial infection and disease. Curr Opin Immunol 2009;21:378-84
11. Kanneganti TD. Central roles of NLRs and inflammasomes in viral infection. Nat Rev Immunol 2010;10:688-98
12. Raupach B, Peuschel SK, Monack DM, Zychlinsky A. Caspase-1-mediated activation of interleukin-1beta (IL-1beta) and IL-18 contributes to innate immune defenses against Salmonella enterica serovar Typhimurium infection. Infect Immun 2006;74:4922-6
13. van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA. Inflammasome activation and IL-1beta and IL-18 processing during infection. Trends Immunol 2011;32:110-16
14. Netea MG, Simon A, van de Veerdonk F, et al. IL-1beta processing in host defense: Beyond the inflammasomes. PLoS Pathog 2010;6:e1000661
15. Rathinam VA, Vanaja SK, Fitzgerald KA. Regulation of inflammasome signaling. Nat Immunol 2012;13:333-2
16. Barker BR, Taxman DJ, Ting JP. Cross-regulation between the IL-1beta/IL-18 processing inflammasome and other inflammatory cytokines. Curr Opin Immunol 2011;23:591-7
17. Fox PC. Autoimmune diseases and Sjogren's syndrome: An autoimmune exocrinopathy. Ann NY Acad Sci 2007;1098:15-21
18. Hedfors E, Lindahl G. Studies on the specificity of the immunohistopathological changes of the salivary glands in Sjogren's syndrome. Clin Exp Rheumatol 1989;7:163-5
19. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. J Autoimmun 2010;34:400-7
20. Turpie B, Yoshimura T, Gulati A, et al. Sjogren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice. Am J Pathol 2009;175:1136-47
21. Katsifis GE, Rekka S, Moutsopoulos NM, et al. Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol 2009;175:1167-77
22. Varin MM, Guerrier T, Devauchelle-Pensec V, et al. In Sjogren's syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation. Autoimmun Rev 2012;11:252-8
23. Abdulahad WH, Kroese FG, Vissink A, Bootsma H. Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome. J Autoimmun 2012;39:103-11
24. Oxholm P, Daniels TE, Bendtzen K. Cytokine expression in labial salivary glands from patients with primary Sjogren's syndrome. Autoimmunity 1992;12:185-91
25. Hamano H, Saito I, Haneji N, et al. Expressions of cytokine genes during development of autoimmune sialadenitis in MRL/lpr mice. Eur J Immunol 1993;23:2387-91
26. Fox RI, Kang HI, Ando D, et al. Cytokine mRNA expression in salivary gland biopsies of Sjogren's syndrome. J Immunol 1994;152:5532-9
27. Hayashi Y, Haneji N, Hamano H. Pathogenesis of Sjogren's syndrome-like autoimmune lesions in MRL/lpr mice. Pathol Int 1994;44:559-68
28. Cauli A, Yanni G, Pitzalis C, et al. Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjogren's syndrome and chronic sialadenitis. Ann Rheum Dis 1995;54:209-15
29. Boumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjogren's syndrome. Br J Rheumatol 1995;34:326-33
30. Chen YT, Lazarev S, Bahrami AF, et al. Interleukin-1 receptor mediates the interplay between CD4+ T cells and ocular resident cells to promote keratinizing squamous metaplasia in Sjogren's syndrome. Lab Invest 2012;92:556-70
31. Chen YT, Nikulina K, Lazarev S, et al. Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjogren's syndrome. Am J Pathol 2010;177:1333-43
32. Takahashi M, Mimura Y, Hamano H, et al. Mechanism of the development of autoimmune dacryodenitis in the mouse model for primary Sjogren's syndrome. Cell Immunol 1996;170:54-62
33. Perrier S, Coussediere C, Dubost JJ, et al. IL-1 receptor antagonist (IL-1RA) gene polymorphism in Sjogren's syndrome and rheumatoid arthritis. Clin Immunol Immunopathol 1998;87:309-13
34. Muraki Y, Tsutsumi A, Takahashi R, et al. Polymorphisms of IL-1 beta gene in Japanese patients with Sjogren's syndrome and systemic lupus erythematosus. J Rheumatol 2004;31:720-5
35. Gerard N, Caillaud M, Martoriati A, et al. The interleukin-1 system and female reproduction. J Endocrinol 2004;180:203-12
36. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 1994;8:1314-25
37. di Giovine FS, Duff GW. Interleukin 1: The first interleukin. Immunol Today 1990;11:13-20
38. Burger D, Dayer JM. Cytokines, acute-phase proteins, and hormones: IL-1 and TNF-alpha production in contact-mediated activation of monocytes by T lymphocytes. Ann N Y Acad Sci 2002;966:464-73
39. Rao DA, Pober JS. Endothelial injury, alarmins, and allograft rejection. Crit Rev Immunol 2008;28:229-48
40. Ben-Sasson SZ, Caucheteux S, Crank M, et al. IL-1 acts on T cells to enhance the magnitude of in vivo immune responses. Cytokine 2011;56:122-5
41. Kobayashi Y, Oppenheim JJ, Matsushima K. Calcium-dependent binding of phosphorylated human pre interleukin 1 alpha to phospholipids. J Biochem 1990;107:666-70
42. Kobayashi Y, Yamamoto K, Saido T, et al. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. Proc Natl Acad Sci USA 1990;87:5548-52
43. Stevenson FT, Turck J, Locksley RM, Lovett DH. The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein. Proc Natl Acad Sci USA 1997;94:508-13
44. Kavita U, Mizel SB. Differential sensitivity of interleukin-1 alpha and -beta precursor proteins to cleavage by calpain, a calcium-dependent protease. J Biol Chem 1995;270:27758-65
45. Walker NP, Talanian RV, Brady KD, et al. Crystal structure of the cysteine protease interleukin-1 beta-converting enzyme: A (p20/p10)2 homodimer. Cell 1994;78:343-52
46. Darmon AJ, Bleackley RC. An interleukin-1beta converting enzyme-like protease is a key component of Fas-mediated apoptosis. J Biol Chem 1996;271:21699-702
47. Miller DK, Myerson J, Becker JW. The interleukin-1 beta converting enzyme family of cysteine proteases. J Cell Biochem 1997;64:2-10
48. Dinarello CA. Interleukin-18. Methods 1999;19:121-32
49. Fantuzzi G, Dinarello CA. Interleukin-18 and interleukin-1 beta: Two cytokine substrates for ICE (caspase-1). J Clin Immunol 1999;19:1-11
50. Alheim K, Bartfai T. The interleukin-1 system: Receptors, ligands, and ICE in the brain and their involvement in the fever response. Ann N Y Acad Sci 1998;840:51-8
51. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010;6:232-41
52. Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J Biol Chem 2011;286:42594-602
53. Tripodi D, Conti F, Rosati M, et al. IL-36 a new member of the IL-1 family cytokines. J Biol Regul Homeost Agents 2012;26:7-14
54. Daun JM, Fenton MJ. Interleukin-1/Toll receptor family members: Receptor structure and signal transduction pathways. J Interferon Cytokine Res 2000;20:843-55
55. Sims JE. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 2002;14:117-22
56. Symons JA, Young PR, Duff GW. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA 1995;92:1714-18
57. Dunne A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: Signal transduction during inflammation and host defense. Sci STKE 2003;2003(171):re3
58. Kracht M, Truong O, Totty NF, et al. Interleukin 1 alpha activates two forms of p54 alpha mitogen-activated protein kinase in rabbit liver. J Exp Med 1994;180:2017-25
59. Freshney NW, Rawlinson L, Guesdon F, et al. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 1994;78:1039-49
60. O'Neill LA. Towards an understanding of the signal transduction pathways for interleukin 1. Biochim Biophys Acta 1995;1266:31-44
61. O'Neill LA. Interleukin-1 signal transduction. Int J Clin Lab Res 1995;25:169-77
62. Reimers JI, Bjerre U, Mandrup-Poulsen T, Nerup J. Interleukin 1 beta induces diabetes and fever in normal rats by nitric oxide via induction of different nitric oxide synthases. Cytokine 1994;6:512-20
63. Cnop M, Welsh N, Jonas JC, et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: Many differences, few similarities. Diabetes 2005;54(Suppl 2):S97-107
64. Tanikawa M, Kim TS, Okuda K, et al. Cell-type specificity of interleukins 1alpha and 1beta on prostaglandin and plasminogen activator production in bovine endometrial cells. Anim Reprod Sci 2009;114:32-42
65. Subramanian N, Bray MA. Interleukin 1 releases histamine from human basophils and mast cells in vitro. J Immunol 1987;138:271-5
66. Theoharides TC, Kempuraj D, Tagen M, et al. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007;217:65-78
67. Ceballos-Olvera I, Sahoo M, Miller MA, et al. Inflammasome-dependent pyroptosis and IL-18 protect against Burkholderia pseudomallei lung infection while IL-1beta is deleterious. PLoS Pathog 2011;7:e1002452
68. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11:633-52
69. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: A clinical perspective. Cell 2010;140:784-90
70. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355:581-92
71. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009;27:621-68
72. Stock TC, Bloom BJ, Wei N, et al. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol 2012;39:720-7
73. Cunnane G, Madigan A, Murphy E, et al. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford) 2001;40:62-9
74. Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J Rheumatol 2004;31:1103-11
75. Botsios C, Sfriso P, Furlan A, et al. Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis. Reumatismo 2007;59(1):32-7
76. Emsley HC, Smith CJ, Georgiou RF, Acute Stroke Investigators. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005;76:1366-72
77. Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 2010;6:158-66
78. Larsen CM, Faulenbach M, Vaag A, et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009;32:1663-8
79. de Jong BA, Huizinga TW, Bollen EL, et al. Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J Neuroimmunol 2002;126:172-9
80. Nikolov NP, Illei GG. Pathogenesis of Sjogren's syndrome. Curr Opin Rheumatol 2009;21:465-70
81. Youinou P, Pers JO. Disturbance of cytokine networks in Sjogren's syndrome. Arthritis Res Ther 2011;13:227
82. Low HZ, Witte T. Aspects of innate immunity in Sjogren's syndrome. Arthritis Res Ther 2011;13:218
83. Katsifis GE, Moutsopoulos NM, Wahl SM. T lymphocytes in Sjogren's syndrome: Contributors to and regulators of pathophysiology. Clin Rev Allergy Immunol 2007;32:252-64
84. Manoussakis MN, Boiu S, Korkolopoulou P, et al. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: Correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum 2007;56:3977-88
85. Sakai A, Sugawara Y, Kuroishi T, et al. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008;181:2898-906
86. Enk C, Oxholm P. Decreased interleukin-1 responsiveness of blood lymphocytes in patients with primary Sjogren's syndrome. Clin Exp Rheumatol 1988;6:67-9
87. Willeke P, Schotte H, Schluter B, et al. Interleukin 1beta and tumour necrosis factor alpha secreting cells are increased in the peripheral blood of patients with primary Sjogren's syndrome. Ann Rheum Dis 2003;62:359-62
88. Eutamene H, Theodorou V, Fioramonti J, Bueno L. Acute stress modulates the histamine content of mast cells in the gastrointestinal tract through interleukin-1 and corticotropin-releasing factor release in rats. J Physiol 2003;553:959-66
89. Tarlow JK, Blakemore AI, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993;91:403-4
90. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995;99:303-10
91. Saito I, Terauchi K, Shimuta M, et al. Expression of cell adhesion molecules in the salivary and lacrimal glands of Sjogren's syndrome. J Clin Lab Anal 1993;7:180-7
92. Hulkkonen J, Pertovaara M, Antonen J, et al. IL-1 gene family haplotypes and Raynaud's phenomenon in primary Sjogren's syndrome. Rheumatology (Oxford) 2002;41:1206-8
93. Camargo JF, Correa PA, Castiblanco J, Anaya JM. Interleukin-1beta polymorphisms in Colombian patients with autoimmune rheumatic diseases. Genes Immun 2004;5:609-14
94. Kang EH, Lee YJ, Hyon JY, et al. Salivary cytokine profiles in primary Sjogren's syndrome differ from those in non-Sjogren sicca in terms of TNF-alpha levels and Th-1/Th-2 ratios. Clin Exp Rheumatol 2011;29:970-6
95. Dubost JJ, Perrier S, Afane M, et al. IL-1 receptor antagonist in saliva; characterization in normal saliva and reduced concentration in Sjogren's syndrome (SS). Clin Exp Immunol 1996;106:237-42
96. Matsumura R, Umemiya K, Kagami M, et al. Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjogren's syndrome. Clin Exp Rheumatol 2002;20:791-8
97. Lin X, Shaw PC, Sze SC, et al. Dendrobium officinale polysaccharides ameliorate the abnormality of aquaporin 5, pro-inflammatory cytokines and inhibit apoptosis in the experimental Sjogren's syndrome mice. Int Immunopharmacol 2011;11:2025-32
98. Zoukhri D, Macari E, Choi SH, Kublin CL. c-Jun NH2-terminal kinase mediates interleukin-1beta-induced inhibition of lacrimal gland secretion. J Neurochem 2006;96:126-35
99. Haneji N, Nakamura T, Takio K, et al. Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren's syndrome. Science 1997;276:604-7
100. Ishimaru N, Yanagi K, Ogawa K, et al. Possible role of organ-specific autoantigen for Fas ligand-mediated activation-induced cell death in murine Sjogren's syndrome. J Immunol 2001;167:6031-7
101. Ishimaru N, Arakaki R, Watanabe M, et al. Development of autoimmune exocrinopathy resembling Sjogren's syndrome in estrogen-deficient mice of healthy background. Am J Pathol 2003;163:1481-90
102. Wang Y, Virji AS, Howard P, et al. Detection of cleaved alpha-fodrin autoantigen in Sjogren's syndrome: Apoptosis and co-localisation of cleaved alpha-fodrin with activated caspase-3 and cleaved poly(ADP-ribose) polymerase (PARP) in labial salivary glands. Arch Oral Biol 2006;51:558-66
103. Jimenez F, Aiba-Masago S, Al Hashimi I, et al. Activated caspase 3 and cleaved poly(ADP-ribose)polymerase in salivary epithelium suggest a pathogenetic mechanism for Sjogren's syndrome. Rheumatology (Oxford) 2002;41:338-42
104. Aiba-Masago S, Masago R, Vela-Roch N, et al. Fas-mediated apoptosis in a rat acinar cell line is dependent on caspase-1 activity. Cell Signal 2001;13:617-24
105. Ishimaru N, Arakaki R, Omotehara F, et al. Novel role for RbAp48 in tissue-specific, estrogen deficiency-dependent apoptosis in the exocrine glands. Mol Cell Biol 2006;26:2924-35
106. Ishimaru N, Arakaki R, Yoshida S, et al. Expression of the retinoblastoma protein RbAp48 in exocrine glands leads to Sjogren's syndrome-like autoimmune exocrinopathy. J Exp Med 2008;205:2915-27
107. Li S, Gallup M, Chen YT, McNamara NA. Molecular mechanism of proinflammatory cytokine-mediated squamous metaplasia in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2010;51:2466-75
108. Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. The role of epithelial cells in the initiation and perpetuation of autoimmune lesions: Lessons from Sjogren's syndrome (autoimmune epithelitis). Lupus 2006;15:255-61
109. Nelson JD, Wright JC. Conjunctival goblet cell densities in ocular surface disease. Arch Ophthalmol 1984;102:1049-51
110. Nishida K, Yamanishi K, Yamada K, et al. Epithelial hyperproliferation and transglutaminase 1 gene expression in Stevens-Johnson syndrome conjunctiva. Am J Pathol 1999;154:331-6
111. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the AIRE protein. Science 2002;298:1395-401
112. Kuroda N, Mitani T, Takeda N, et al. Development of autoimmunity against transcriptionally unrepressed target antigen in the thymus of AIRE-deficient mice. J Immunol 2005;174:1862-70
113. Chen YT, Li S, Nikulina K, et al. Immune profile of squamous metaplasia development in autoimmune regulator-deficient dry eye. Mol Vis 2009;15:563-76
114. Norheim KB, Harboe E, Gøransson LG, Omdal R. Interleukin-1 inhibition and fatigue in primary Sjogren's syndrome-a double blind, randomised clinical trial. PLoS One 2012;7:e30123